Spago Nanomedical AB (publ) (STO:SPAGO)

Market Cap	91.41M -3.1%
Revenue (ttm)	3.81M -38.1%
Net Income	-26.28M
EPS	-0.05
Shares Out	798.38M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,900
Open	0.1105
Previous Close	0.1145
Day's Range	0.1105 - 0.1145
52-Week Range	0.0842 - 0.3700
Beta	1.30
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 6, 2026

About Spago Nanomedical AB

Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under preclinical development stage. The company wa...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 5
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SPAGO

Financial Performance

In 2025, Spago Nanomedical AB's revenue was 4.47 million, a decrease of -32.85% compared to the previous year's 6.66 million. Losses were -26.55 million, -18.32% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 27, 2026

Data Sources Report a data error